This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lazzerini, P.E. Articles by Laghi Pasini, F. Search for Related Content PubMed PubMed Citation Articles by Lazzerini, P.E. Articles by Laghi Pasini, F. Social Bookmarking                   What's this?

Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?

Divisions of Clinical Immunology, University of Siena, Siena, Italy

P.L. Capecchi

Divisions of Clinical Immunology, University of Siena, Siena, Italy

E. Selvi

Rheumatology, Department of Clinical Medicine and Immunological Sciences, University of Siena, Siena, Italy

S. Lorenzini

Rheumatology, Department of Clinical Medicine and Immunological Sciences, University of Siena, Siena, Italy

S. Bisogno

Rheumatology, Department of Clinical Medicine and Immunological Sciences, University of Siena, Siena, Italy

M. Galeazzi

Rheumatology, Department of Clinical Medicine and Immunological Sciences, University of Siena, Siena, Italy

F. Laghi Pasini

Divisions of Clinical Immunology, University of Siena, Siena, Italy

Epidemiological studies conducted over the past 25 years have provided ample support for the association of mild hyperhomocysteinemia (HHcy) with an elevated risk of atherothrombosis. Since autoimmune disorders (AD) are frequently associated with relevant and early signs of atherothrombotic damage not adequately explained by the traditional risk factors involved in the onset of cardiovascular disease (CVD), a large interest has been shown to the putative role of mild HHcy in this setting. On the basis of such considerations, we focused the attention on the relationship between homocysteine (Hcy) and CVD in patients affected with autoimmune diseases, reviewing the most recent literature data and also providing our original experience. Although the large amount of available studies clearly shows that HHcy represents a common finding in patients affected with several autoimmune diseases, the actual role of Hcy in the development of CVD in the course of AD is not clear yet, perhaps, with the only exception of the systemic lupus erythematosus. In the other conditions, the role of Hcy in the pathogenesis of vascular complications is still a matter of debate, as the result of conflicting reports and/or lack of an adequate body of investigation. Lupus (2007) 16, 852—862.

Key Words: autoimmune diseases • Behçet's disease • cardiovascular disease • connective tissue diseases • homocysteine • inflammatory bowel disease • rheumatoid arthritis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?